Positive context积极背景
Stocks股票 / Health Care / PTCT
PTC Therapeutics, Inc. · Health Care
PTCT US listed · USD美股 · 美元
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.PTC Therapeutics, Inc. 是一家美国制药公司，专注于开发口服小分子药物和基因疗法，通过靶向孤儿病中的转录后控制（PTC）机制来调节基因表达。
Mid cap中盘 · $5B
Health Care
S&P 600标普600小盘Russell 2000罗素2000
Distressed困境股
$62.67
+$0.39 · +0.63%
52w low52周低 $56.62high高 $91.10
Hold off — timing against you暂缓 — 时机不利
Downtrend — stand aside until a new cycle low forms and confirms.下跌趋势——观望，直至新的周期低点形成并确认。
As of 2026-09-28截至 2026-09-28
Company intelligence公司情报
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考；使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动，请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Pressure context压力背景
History mode历史模式
Context only仅供参考 · not a signal or recommendation不构成信号或建议
Narrative claims may await line-level citation; verify in the transcript.叙述性内容可能仍待逐行引用，请在电话会原文中核对。
Price chart价格图表
daily · interactive日线 · 可交互
Open in Terminal打开终端 ↗
Loading chart…图表加载中…
The interactive chart could not load here.互动图表暂时无法在此加载。
Open the live chart in Terminal在终端中打开实时图表 ↗
Candles, volume and moving averages — pan and zoom inside the chart.蜡烛图、成交量与均线 — 图内可缩放拖动。
MMastermind Terminal — live & interactiveMastermind 终端 — 实时互动 ↗
Technicals技术面
daily bars日线数据 · 2026-09-28
Momentum (RSI 14)动量（RSI 14）
33
Depressed偏低
vs 50-day average相对50日均线
-11.6% below下方
Below trend跌破趋势
vs 200-day average相对200日均线
-13.5% below下方
Long trend down长期向下
Volatility波动率
38th percentile第38百分位
These readings feed the stance at the top — one source per number, refreshed nightly.以上读数构成页首的引擎立场 — 每个数字只有一个来源，每晚更新。
Earnings财务业绩
next report下次财报 2026-11-0336
Estimates being cut预期下调
Beat in 3 of last 4 quarters近 4 季中 3 季超预期
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度（近几个季度） · average平均 39.0%
Valuation估值
Looks cheap vs sector相对行业偏便宜| Multiple指标 | PTCT | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 7.48x | 29.58 | |
| P/S市销率 | 2.95x | 3.19 | |
| Earnings yield盈利收益率 | 13.38% | 2.56 | |
| FCF yield自由现金流收益率 | 13.76% | 4.11 | |
| EV/EBITDA企业价值/EBITDA | 5.18x | 18.26 | |
| P/FCF市值/自由现金流 | 7.27x | 21.34 |
"Cheaper than" = share of sector peers trading richer on that multiple.「相对便宜」= 行业中该指标估值更高的同行占比。
Financials财务数据
fiscal years财年Revenue营业收入
$1.7B2025
20202025
5-yr growth5年复合增速 35.4%
Earnings per share每股收益
$7.782025
20202025
Free cash flow自由现金流
$702.3M2025
20202025
Operating margin营业利润率
50.1%
Net margin净利率
39.5%
FCF margin自由现金流利润率
41.1%
Balance-sheet quality财务体质 6/8
Bankruptcy risk: distress zone破产风险：警戒区
Return on equity股本回报率 -333%
Warning警示
Leverage杠杆
Net debt / EBITDA净债务/EBITDA-0.46
Current ratio流动比率2.35
Capital allocation资本配置
Stock-based comp股权薪酬$74.5M
Share count change (1y)股数变化（1年）+4.9%
Debt coming due到期债务
SEC filingsSEC 文件Debt schedule not loaded yet.到期债务尚未加载。
This panel is still catching up to the SEC filings for this listing. Check back soon — nothing is being estimated in its place.本面板仍在同步该证券的 SEC 文件，请稍后再查看；此处不作任何估算替代。
A cash-flow scenario is unavailable until the filing inputs are verified.报告数据核实前，现金流情景暂不可用。
Capital-need coverage is not available for this issuer yet.该发行人的资本需求覆盖信息暂不可用。
Reported facts remain separate from the cash-flow scenario until identity and filing provenance are confirmed.在确认身份与报告来源之前，已披露事实与现金流情景保持分离。
Research context only — reported figures from SEC filings, not a rating, a signal or investment advice.仅供研究参考 — 数据摘自 SEC 文件披露口径，不构成评级、信号或投资建议。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
Death cross on PTCTPTCT 死叉
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向： -$24.1M net (0 buyers, 10 sellers)-$24.1M 净值（0 买家，10 卖家）
Concentrated ownership集中持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | As of截至 |
|---|---|---|---|---|
| Polen Capital Management | C | New position新建仓 | 0.0% | 2026-06-30 |
| RTW Investments | B | Holding持有 | 5.4% | 2026-06-30 |
Signal history信号历史
engine events引擎事件
UNCONFIRMED TURN → DOWNTREND未确认转向 → 下跌趋势
AVOID. Failed cycle — price broke below the low that started this cycle, which historically means the larger trend is rolling over (~80% of cases)回避。失败周期——价格跌破了启动本周期的低点，历史上这通常意味着更大的趋势正在掉头向下（约 80% 的情形）
Sep 18, 2026
Death cross on PTCTPTCT 死叉
The 50-day average crossed below the 200-day — a slow, widely-watched bearish trend signal. $65.37.50日均线下穿200日均线 — 一个滞后但广受关注的看空趋势信号。$65.37。
Sep 17, 2026
DOWNTREND → UNCONFIRMED TURN下跌趋势 → 未确认转向
HIGH-RISK · NIMBLE ONLY高风险 · 仅限灵活操作
Sep 16, 2026
PTCT StochRSI turned up from oversoldPTCT StochRSI自超卖区上行
StochRSI popped back above 20 — the earliest oscillator heads-up that downside momentum is easing. $67.59.StochRSI重回20上方 — 下行动量趋缓的最早预警。$67.59。
Sep 9, 2026
NEARING A LOW → DOWNTREND接近低点 → 下跌趋势
AVOID回避
Sep 8, 2026
UNCONFIRMED TURN → NEARING A LOW未确认转向 → 接近低点
GET READY准备
Sep 8, 2026
PTCT daily MACD crossed downPTCT 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $68.81.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$68.81。
Sep 4, 2026
PTCT broke down vs the marketPTCT 相对市场走弱
Relative strength vs SPY crossed below the 10th percentile of the last 90 days — weakness often leads price. $69.30.相对标普500的强弱下穿近90日的第10百分位 — 走弱常先于价格。$69.30。
Aug 31, 2026
PTCT broke down vs the marketPTCT 相对市场走弱
Relative strength vs SPY crossed below the 10th percentile of the last 90 days — weakness often leads price. $69.54.相对标普500的强弱下穿近90日的第10百分位 — 走弱常先于价格。$69.54。
Showing the last 15 of显示最近15条，共 256 signals条信号
Company profile公司档案
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.PTC Therapeutics, Inc. 是一家美国制药公司，专注于开发口服小分子药物和基因疗法，通过靶向孤儿病中的转录后控制（PTC）机制来调节基因表达。
Style DNA — how it trades vs the market风格基因 — 相对市场的交易特征
Value价值
Below market低于市场
Quality质量
Above market高于市场
Investment资本投入
Below market低于市场
Low volatility低波动
Below market低于市场
Low market beta低市场敏感度
Below market低于市场
Earnings quality盈利质量
Above market高于市场
Short interest空头兴趣
Above market高于市场
Watch items — what could change the story关注项 — 可能改变故事的因素
- Inventory build
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Statistics — full detail统计数据 — 完整明细
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（静态） | 7.5× | 29.6× | 98% |
| Price / Sales市销率 | 3.0× | 3.2× | 52% |
| EV / EBITDAEV/EBITDA | 5.2× | 18.3× | 96% |
| Earnings yield盈利收益率 | 13.4% | 2.6% | 99% |
| Free-cash-flow yield自由现金流收益率 | 13.9% | 5.5% | 92% |
Relative strength相对强度
vs market, 1 month相对大盘（1个月）
78/100 — stronger than most强于多数
vs market, 3 months相对大盘（3个月）
8/100 — weaker than most弱于多数
vs market, 6 months相对大盘（6个月）
30/100 — weaker than most弱于多数
vs market, 12 months相对大盘（12个月）
50/100 — middle of the pack居中
Rank in sector行业内排名
#60 / 173
0–100 percentile of total return vs all covered stocks.总回报在全部覆盖股票中的百分位（0–100）。
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -4.1% | +1.3% |
| 1 Month近1月 | -13.8% | +0.9% |
| 3 Months近3月 | -25.8% | +6.1% |
| 6 Months近6月 | -5.2% | +22.3% |
| Year to date年初至今 | -18.3% | +13.8% |
| 1 Year近1年 | +8.4% | +18.5% |
| 3 Years近3年 | +177.3% | +87.8% |
Trading information交易信息
Beta vs market贝塔
0.69
Volatility rank波动率分位
38th pctile
Short interest空头占比
11.9% of float
Market cap市值
$5B
EPS (trailing)每股收益
$8.38
Off 52-week high距52周高点
-30.0%
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Financials — full detail财务数据 — 完整明细
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $381M | $539M | $699M | $938M | $807M | $1.7B |
| EPS每股收益 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $7.78 |
| Free cash flow自由现金流 | $-212M | $-280M | $-389M | $-187M | $-114M | $702M |
| Gross margin毛利率 | — | — | — | — | — | — |
| Net margin净利率 | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| FCF margin自由现金流利润率 | -55.7% | -51.9% | -55.6% | -19.9% | -14.2% | 40.6% |
Latest fiscal year最近财年
Revenue (FY)营业收入（财年）
$1.7B
Net income净利润
$683M
Operating cash flow经营现金流
$711M
Total assets总资产
$2.9B
Shareholder equity股东权益
$-205M
Long-term debt长期负债
$286M
Shares outstanding总股本
0.08B
Returns & growth回报与增长
Return on equity股本回报率
-332.7%
Return on assets资产回报率
23.6%
Debt / assets负债/资产
9.9%
Asset growth资产增速
+70.0%
Accounting quality checks会计质量检查
- Earnings quality: accruals trending up over 6 fiscal years — earnings increasingly not cash-backed盈利质量：应计利润在 6 个财年间走高——盈利的现金支撑减弱
- Working capital: inventory & receivables lean vs sales营运资本：存货与应收相对销售保持精简
- Capital discipline: share count +16.9% over 6 years (dilution)资本纪律：股本 6 年增加 16.9%（稀释）
- Balance sheet: Altman Z 1.68 — distress zone资产负债表：Altman Z 1.68——困境区
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Technicals — full detail技术面 — 完整明细
Indicator readings指标读数
RSI (14-day)RSI（14日）
33
RSI (2-day)RSI（2日）
33
vs 20-day average相对20日均线
-6.7%
vs 50-day average相对50日均线
-11.6%
vs 200-day average相对200日均线
-13.5%
Golden cross (50>200)金叉（50>200）
not in effect未生效
MACDMACD
below signal位于信号线下方
Timeframe alignment多周期共振
Daily日线
momentum down动能向下
3-day3日线
momentum down动能向下
Weekly周线
momentum down动能向下
When daily through monthly point the same way, moves carry further.当日线到月线方向一致时，行情往往更有延续性。
Volatility regime波动状态
Range width percentile波幅宽度分位
59/100
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Earnings — full detail财务业绩 — 完整明细
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $0.92 | $-0.17 | +641.2% |
| Mar 2026 | $-0.03 | $-0.45 | +93.3% |
| Dec 2025 | $-1.67 | $-0.21 | -695.2% |
| Sep 2025 | $0.20 | $-1.19 | +116.8% |
Estimate revisions预期修正
Analysts covering覆盖分析师
3
Estimate direction预期调整方向
mostly cutting多数下调
Estimate change, 90 days预期变化（90天）
-3.8%
Net upgrades, 30 days净上调（30天）
-1
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Ownership — full detail持仓 — 完整明细
Tracked funds holding it跟踪基金持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | Position市值 |
|---|---|---|---|---|
| Polen Capital Management | C | New position新建仓 | 0.0% | $2M |
| RTW Investments | B | Holding持有 | 5.4% | $632M |
Fund positioning基金持仓概览
Tracked funds in the name持有该股的跟踪基金
2
Buying vs selling买入vs卖出
1 : 0
Quarterly trend季度趋势
{'direction': 'accumulating', 'n_quarters': 12, 'holders_first': 1, 'holders_last': 2, 'holders_delta': 1, 'value_change_pct': 291.0, 'from_period': '2023-09-30', 'to_period': '2026-06-30', 'available_on': '2026-08-14', 'available_on_first': '2023-11-14', 'holders_series': [1, 1, 1, 1, 1, 2, 1, 1, 1, 1, 1, 2]}{'direction': 'accumulating', 'n_quarters': 12, 'holders_first': 1, 'holders_last': 2, 'holders_delta': 1, 'value_change_pct': 291.0, 'from_period': '2023-09-30', 'to_period': '2026-06-30', 'available_on': '2026-08-14', 'available_on_first': '2023-11-14', 'holders_series': [1, 1, 1, 1, 1, 2, 1, 1, 1, 1, 1, 2]}
Insiders & shorts内部人与空头
Insider net buying (6 months)内部人净买入（6个月）
-$24.1M
Insider buyers vs sellers内部人买家vs卖家
0 : 10
Short interest空头占流通盘
11.9%
Days to cover回补天数
11.0
Short interest change空头变化
-0.9%
Recent fund flows近期基金流向
SPDR S&P BiotechSPDR S&P Biotech
accumulating持续增持
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Seasonality — full detail季节性 — 完整明细
Strongest month最强月份
May · 100%
Weakest month最弱月份
Jan · 33%
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 33% | -0.3% | 3 |
| Feb2月 | 67% | +8.7% | 3 |
| Mar3月 | 67% | +0.8% | 3 |
| Apr4月 | 33% | -0.2% | 3 |
| May5月 | 100% | +14.1% | 3 |
| Jun6月 | 67% | +0.8% | 3 |
| Jul7月 | 67% | +7.5% | 3 |
| Aug8月 | 75% | +2.6% | 4 |
| Sep9月 | 50% | +5.5% | 4 |
| Oct10月 | 67% | +9.6% | 3 |
| Nov11月 | 100% | +22.2% | 3 |
| Dec12月 | 67% | +5.0% | 3 |
History is a tendency, not a promise — small samples wobble.历史规律只是倾向而非保证 — 样本少时波动大。
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。